(Applicant's description) This Comprehensive Cancer Center is based at the University of Alabama at Birmingham (UAB) and the UAB Medical Center. The Center has been funded by NCI continuously since 1971 and currently has 228 faculty members, $49.3 million of research support, and 138,000 square feet of Cancer Center controlled space. The Cancer Center administratively functions as a matrix organization with involvement of faculty and resources from 36 departments in seven Schools of the institution. The Center evaluates 3,000 new cancer cases annually and places about 700 patients on clinical trials. The Center has 100 cancer beds in the University of Alabama Hospital and extensive modern ambulatory facilities in The Kirklin Clinic. It has a strong emphasis on interdisciplinary and translational research efforts. It is organized into seven major program areas: Immunology, Structured Biology, Molecular Genetics, Virology, Experimental Therapeutics, Neuro-Oncology, and Cancer Prevention and Control. It has a developmental program in Breast/Ovary/ Prostate cancer. The Center supports 12 shared facilities including Biostatistics, Clinical Studies, Tissue Procurement, Cell Marker/In Situ Hybridization, Electron Microscopy, Fermentation, Mass Spectroscopy, Media Preparation, Oligonucleotide Synthesis, Peptide Synthesis and Analysis, Nuclear Magnetic Resonance, and X-ray Crystallography. This proposal also requests shared facility support for a Transgenic Animal. Pathogen Free Rodent, Radiolabeling, Protein Purification and Micro-Analysis, and Clinical Molecular Biology facility. In addition, the Center has an active developmental effort with annual pilot research project funding and funding for support of new investigator recruitment and/or start-up. A formal planning process involving internal committees and external consultants provides advice to the senior leadership of the Center. The Center has strong support from the university and a productive record of successful competitive grant support and scientific publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA013148-28S2
Application #
6153082
Study Section
Cancer Center Support Review Committee (CCS)
Program Officer
Silkensen, Shannon M
Project Start
1985-07-01
Project End
2000-02-29
Budget Start
1999-03-12
Budget End
2000-02-29
Support Year
28
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Kasten, Benjamin B; Oliver, Patsy G; Kim, Harrison et al. (2018) 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci 19:
Subramaniam, Akila; Blanchard, Christina T; Erickson, Britt K et al. (2018) Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 132:20-27
Garner, Evan F; Williams, Adele P; Stafman, Laura L et al. (2018) FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. Sci Rep 8:6913
Stoll, Matthew L; Weiss, Pamela F; Weiss, Jennifer E et al. (2018) Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther 20:14
Locke, Landon W; Kothandaraman, Shankaran; Tweedle, Michael et al. (2018) Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb) 108:201-210
Fancy, Romone M; Kim, Harrison; Napier, Tiara et al. (2018) Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. J Cell Biochem 119:6216-6230
Barrington, David A; Champion, Macie L; Boitano, Teresa K L et al. (2018) Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. Gynecol Oncol 149:337-340
Banerjee, N Sanjib; Wang, Hsu-Kun; Beadle, James R et al. (2018) Evaluation of ODE-Bn-PMEG, an acyclic nucleoside phosphonate prodrug, as an antiviral against productive HPV infection in 3D organotypic epithelial cultures. Antiviral Res 150:164-173
Keene, Kimberly S; King, Tari; Hwang, E Shelley et al. (2018) Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer 4:34
Kleinpeter, Alex B; Jureka, Alexander S; Falahat, Sally M et al. (2018) Structural analyses reveal the mechanism of inhibition of influenza virus NS1 by two antiviral compounds. J Biol Chem 293:14659-14668

Showing the most recent 10 out of 747 publications